A quick peek into the report
Table of Contents
1.1 Market Definition
1.2 Market Footprint and Growth Potential
1.3 Sample Processed in Long-Read Sequencing
1.4 Install Base of Oxford Nanopore Technologies plc
1.5 Preferred Nucleic Acid Purification Kits for Long-Read Sequencing
1.6 COVID-19 Impact on Global Long-Read Sequencing Market
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.3.1 Decreasing Cost of Sequencing
2.3.2 Global Increase in Cancer Prevalence
2.3.3 Increasing Number of Population Genomics Initiatives
2.4 Market Restraints
2.4.1 Lack of High Complexity Genomic Testing Centers in High Potential Markets
2.4.2 Challenges Pertaining to Genomic Data Storage
2.4.3 Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities
2.5 Market Opportunities
2.5.1 Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations
2.5.2 Novel Diagnostic Applications
3.1 Overview
3.2 Legal Requirements and Framework in the U.S.
3.2.1 FDA Regulation
3.2.2 Centers for Medicare and Medicaid Services (CMS) Regulation
3.3 Legal Requirements and Framework in Europe
3.4 Legal Requirements and Framework in Asia-Pacific
3.4.1 China
3.4.2 Japan
4.1 Acquisitions
4.2 Synergistic Activities
4.3 Product Launches and Upgradations
4.4 Market Share Analysis (by Company), 2019 and 2020
4.5 Growth Share Analysis
4.5.1 Growth Share Analysis (by Technology)
4.5.2 Growth Share Analysis (by Application)
5.1 Overview
5.2 Products
5.2.1 Systems
5.2.2 Kits and Assays
5.2.2.1 Sequencing Reagents
5.2.2.2 Library Preparation Reagents
5.2.2.3 Nucleic Acid Extraction Reagents
5.2.3 Software
5.3 Services
6.1 Overview
6.2 Single-Molecule Real-Time (SMRT) Sequencing
6.3 Nanopore Sequencing
6.4 Synthetic Long-Read Sequencing
6.5 Other Sequencing Technologies
7.1 Overview
7.2 Oncology
7.3 Infectious Diseases
7.4 Rare Diseases
7.5 Genetic Disorders
7.6 Metabolic Disorders
7.7 Translational Research
8.1 Overview
8.2 Academic and Research Institutions
8.3 Pharma and Biotech Companies
8.4 Clinical Laboratories
8.5 Hospitals and Clinics
8.6 Other End Users
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Netherlands
9.3.7 Russia
9.3.8 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 South Korea
9.4.5 Australia
9.4.6 Singapore
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin-America
9.6 Rest-of-the-World (RoW)
10.1 Overview
10.2 Agilent Technologies, Inc.
10.2.1 Company Overview
10.2.2 Role of Agilent Technologies, Inc. in the Global Long-Read Sequencing Market
10.2.3 Financials
10.2.4 Key Insights About Financial of the Company
10.2.5 SWOT Analysis
10.3 Beijing Genomics Institute (BGI) Genomics Co., Ltd
10.3.1 Company Overview
10.3.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Long-Read Sequencing Market
10.3.3 SWOT Analysis
10.4 Bionano Genomics, Inc.
10.4.1 Company Overview
10.4.2 Role of Bionano Genomics, Inc. in the Global Long-Read Sequencing Market
10.4.3 Financials
10.4.4 Key Insights About Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Circulomics Inc
10.5.1 Company Overview
10.5.2 Role of Circulomics Inc in Global Long-Read Sequencing Market
10.5.3 SWOT Analysis
10.6 F. Hoffmann-La Roche Ltd
10.6.1 Company Overview
10.6.2 Role of F. Hoffmann-La Roche Ltd in the Global Long-Read Sequencing Market
10.6.3 Financials
10.6.4 Key Insights About Financial Health of the Company
10.6.5 SWOT Analysis
10.7 Illumina, Inc.
10.7.1 Company Overview
10.7.2 Role of Illumina, Inc. in the Global Long-Read Sequencing Market
10.7.3 Financials
10.7.4 Key Insights About Financial Health of the Company
10.7.5 SWOT Analysis
10.8 Longas Technologies Pty Ltd
10.8.1 Company Overview
10.8.2 Role of Longas Technologies Pty Ltd in the Global Long-Read Sequencing Market
10.8.3 SWOT Analysis
10.9 Novogene Co., Ltd.
10.9.1 Company Overview
10.9.2 Role of Novogene Co., Ltd. in the Global Long-Read Sequencing Market
10.9.3 SWOT Analysis
10.10 Oxford Nanopore Technologies plc
10.10.1 Company Overview
10.10.2 Role of Oxford Nanopore Technologies plc in the Global Long-Read Sequencing Market
10.10.3 Financials
10.10.4 Key Insights About Financial Health of the Company
10.10.5 SWOT Analysis
10.11 Pacific Biosciences of California, Inc.
10.11.1 Company Overview
10.11.2 Role of Pacific Biosciences of California, Inc. in the Global Long-Read Sequencing Market
10.11.3 Financials
10.11.4 Key Insights About Financial Health of the Company
10.11.5 SWOT Analysis
10.12 PerkinElmer, Inc.
10.12.1 Company Overview
10.12.2 Role of PerkinElmer Inc. in the Global Long-Read Sequencing Market
10.12.3 Financials
10.12.4 SWOT Analysis
10.13 QIAGEN
10.13.1 Company Overview
10.13.2 Role of QIAGEN in the Global Long-Read Sequencing Market
10.13.3 Financials
10.13.4 Key Insights About Financial Health of the Company
10.13.5 SWOT Analysis
10.14 Quantapore, Inc.
10.14.1 Company Overview
10.14.2 Role of the Quantapore, Inc. in the Global Long-Read Sequencing Market
10.14.3 SWOT Analysis
10.15 Thermo Fisher Scientific Inc.
10.15.1 Company Overview
10.15.2 Role of Thermo Fisher Scientific Inc. in the Global Long-Read Sequencing Market
10.15.3 Financials
10.15.4 Key Insights About Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Snapshot
10.16.1 Stratos Genomics
10.16.1.1 Company Overview
10.16.1.2 Role of Stratos Genomics in the Global Long-Read Sequencing Market
Table 1: Likert Scale
Table 2: Impact Analysis of Market Drivers
Table 3: Impact Analysis of Market Restraints
Table 4: Systems Offered by Key Players
Table 5: Kits and Assays Offered by Key Players
Table 6: Sequencing Reagents Offered by Key Players
Table 7: Library Preparation Reagents Offered by Key Players
Table 8: Nucleic Acid Extraction Reagents Offered by Key Players
Table 9: Services Offered by Key Players
Figure 1: Annual NIH Funding in Human Genomics Research, FY2013-FY2019
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Long-Read Sequencing Market
Figure 3: Global Long-Read Sequencing Market (by Products and Services), $Million, 2020 vs. 2030
Figure 4: Global Long-Read Sequencing Market (by Technology), $Million, 2020 vs. 2030
Figure 5: Global Long-Read Sequencing Market (by Application), $Million, 2020 vs. 2030
Figure 6: Global Long-Read Sequencing Market (by End User), $Million, 2020 vs. 2030
Figure 7: Global Long-Read Sequencing Market Snapshot
Figure 8: Global Long-Read Sequencing Market: Segmentation
Figure 9: Global Long-Read Sequencing Market: Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Long-Read Sequencing Market, $Million, 2020-2030
Figure 14: Sample Processed Long-Read Sequencing, 2019-2026
Figure 15: Install Base of Oxford Nanopore Technologies plc, 2019-2026
Figure 16: Global Long-Read Sequencing Market: COVID-19 Impact
Figure 17: Decreasing Cost and Increasing Output (TB) of Genome Sequencing, 2009-2025
Figure 18: Global Cancer Burden, 2019
Figure 19: FDA IVD Classification and Regulatory Process
Figure 20: Key Changes in EU IVD Regulation 2017/746
Figure 21: Medical Device Regulatory Approval Process in China
Figure 22: Share of Key Developments and Strategies, January 2017–May 2021
Figure 23: Share of Acquisitions (by Company), January 2017-May 2021
Figure 24: Synergistic Activities Share (by Company), January 2018-May2021
Figure 25: Number of Product Launches and Upgradations (by Company), January 2017–May 2021
Figure 26: Market Share Analysis for Global Long-Read Sequencing Market, 2019 and 2020
Figure 27: Growth Share Analysis for Global Long-Read Sequencing Market (by Technology), 2020-2031
Figure 28: Growth Share Analysis for Global Long-Read Sequencing Market (by Application), 2020-2031
Figure 29: Global Long-Read Sequencing Market (by Products and Services)
Figure 30: Global Long-Read Sequencing Market (by Products and Services), 2020-2030
Figure 31: Global Long-Read Sequencing Market (Products), $Million, 2020-2030
Figure 32: Global Long-Read Sequencing Market (Systems), $Million, 2020-2030
Figure 33: Global Long-Read Sequencing Market (Kits and Assays), $Million, 2020-2030
Figure 34: Global Long-Read Sequencing Market (Sequencing Reagents), $Million, 2020-2030
Figure 35: Global Long-Read Sequencing Market (Library Preparation Reagents), $Million, 2020-2030
Figure 36: Global Long-Read Sequencing Market (Nucleic Acid Extraction Reagents), $Million, 2020-2030
Figure 37: Global Long-Read Sequencing Market (Software), $Million, 2020-2030
Figure 38: Global Long-Read Sequencing Market (Services), $Million, 2020-2030
Figure 39: Global Long-Read Sequencing Market (by Service), 2020-2030
Figure 40: Global Long-Read Sequencing Market (by Technology)
Figure 41: Global Long-Read Sequencing Market (by Technology), 2020-2030
Figure 42: Global Long-Read Sequencing Market (SMRT Sequencing), $Million, 2020-2030
Figure 43: Global Long-Read Sequencing Market (Nanopore Sequencing), $Million, 2020-2030
Figure 44: Global Long-Read Sequencing Market (Synthetic Long-Read Sequencing), $Million, 2020-2030
Figure 45: Global Long-Read Sequencing Market (Other Sequencing Technologies), $Million, 2020-2030
Figure 46: Global Long-Read Sequencing Market (by Application)
Figure 47: Global Long-Read Sequencing Market (by Application), $Million, 2020-2030
Figure 48: Global Long-Read Sequencing Market (Oncology), $Million, 2020-2030
Figure 49: Global Long-Read Sequencing Market (Infectious Diseases), $Million, 2020-2030
Figure 50: Global Long-Read Sequencing Market (Rare Diseases), $Million, 2020-2030
Figure 51: Global Long-Read Sequencing Market (Genetic Disorders), $Million, 2020-2030
Figure 52: Global Long-Read Sequencing Market (Metabolic Disorders), $Million, 2020-2030
Figure 53: Global Long-Read Sequencing Market (Translational Research), $Million, 2020-2030
Figure 54: Global Long-Read Sequencing Market (by End User)
Figure 55: Global Long-Read Sequencing Market (by End User), $Million, 2020-2030
Figure 56: Global Long-Read Sequencing Market (Academic and Research Institutions), $Million, 2020-2030
Figure 57: Global Long-read Sequencing Market (Pharma and Biotech Companies), $Million, 2020-2030
Figure 58: Global Long-read Sequencing Market (Clinical Laboratories), $Million, 2020-2030
Figure 59: Global Long-read Sequencing Market (Hospitals and Clinics), $Million, 2020-2030
Figure 60: Global Long-Read Sequencing Market (Other End Users), $Million, 2020-2030
Figure 61: Global Long-Read Sequencing Market (by Region), 2020 and 2030
Figure 62: Global Long-Read Sequencing Market (by Region), $Million, 2020-2030
Figure 63: Global Long-Read Sequencing Market (by Region), 2020-2030
Figure 64: North America Long-Read Sequencing Market, $Million, 2020-2030
Figure 65: North America: Market Dynamics
Figure 66: North America Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 67: U.S. Long-Read Sequencing Market, $Million, 2020-2030
Figure 68: Canada Long-Read Sequencing Market, $Million, 2020-2030
Figure 69: Europe Long-Read Sequencing Market, $Million, 2020-2030
Figure 70: Europe: Market Dynamics
Figure 71: Europe Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 72: Germany Long-Read Sequencing Market, $Million, 2020-2030
Figure 73: U.K. Long-Read Sequencing Market, $Million, 2020-2030
Figure 74: France Long-Read Sequencing Market, $Million, 2020-2030
Figure 75: Italy Long-Read Sequencing Market, $Million, 2020-2030
Figure 76: Spain Long-Read Sequencing Market, $Million, 2020-2030
Figure 77: Netherlands Long-Read Sequencing Market, $Million, 2020-2030
Figure 78: Russia Long-Read Sequencing Market, $Million, 2020-2030
Figure 79: Rest-of-Europe Long-Read Sequencing Market, $Million, 2020-2030
Figure 80: Asia-Pacific Long-Read Sequencing Market, $Million, 2020-2030
Figure 81: APAC: Market Dynamics
Figure 82: APAC Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 83: China Long-Read Sequencing Market, $Million, 2020-2030
Figure 84: Japan Long-Read Sequencing Market, $Million, 2020-2030
Figure 85: India Long-Read Sequencing Market, $Million, 2020-2030
Figure 86: South Korea Long-Read Sequencing Market, $Million, 2020-2030
Figure 87: Australia Long-Read Sequencing Market, $Million, 2020-2030
Figure 88: Singapore Long-Read Sequencing Market, $Million, 2020-2030
Figure 89: RoAPAC Long-Read Sequencing Market, $Million, 2020-2030
Figure 90: Latin America Long-Read Sequencing Market, $Million, 2020-2030
Figure 91: Latin America: Market Dynamics
Figure 92: Latin America Long-Read Sequencing Market (by Country), $Million, 2020-2030
Figure 93: Brazil Long-Read Sequencing Market, $Million, 2020-2030
Figure 94: Mexico Long-Read Sequencing Market, $Million, 2020-2030
Figure 95: Rest-of-Latin America Long-Read Sequencing Market, $Million, 2020-2030
Figure 96: RoW Long-Read Sequencing Market, $Million, 2020-2030
Figure 97: Total Number of Companies Profiled
Figure 98: Agilent Technologies, Inc.: Product Portfolio
Figure 99: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 100: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 101: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 102: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 103: Agilent Technologies, Inc.: SWOT Analysis
Figure 104: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product Portfolio
Figure 105: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
Figure 106: Bionano Genomics, Inc.: Product Portfolio
Figure 107: Bionano Genomics, Inc.: Overall Financials, 2018-2020
Figure 108: Bionano Genomics, Inc.: R&D Expenditure, 2018-2020
Figure 109: Bionano Genomics, Inc.: SWOT Analysis
Figure 110: Circulomics Inc: Product Portfolio
Figure 111: Circulomics Inc: SWOT Analysis
Figure 112: F. Hoffmann-La Roche Ltd: Portfolio
Figure 113: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 114: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
Figure 115: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
Figure 116: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 117: F. Hoffmann-La Roche: SWOT Analysis
Figure 118: Illumina, Inc.: Overall Financials, 2018-2020
Figure 119: Illumina, Inc.: Revenue (by Segment), 2018-2020
Figure 120: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 121: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 122: Illumina, Inc.: SWOT Analysis
Figure 123: : Longas Technologies Pty Ltd: Product Portfolio
Figure 124: Longas Technologies Pty Ltd: SWOT Analysis
Figure 125: Novogene Corporation: SWOT Analysis
Figure 1: Oxford Nanopore Technologies plc: Product Offerings
Figure 2: Oxford Nanopore Technologies plc: Overall Financials, $Million, 2018-2020
Figure 3: Oxford Nanopore Technologies plc: Revenue (by Segment), $Million, 2018-2020
Figure 4: Oxford Nanopore Technologies plc: Revenue (by Region), $Million, 2018-2020
Figure 5: Oxford Nanopore Technologies plc: R&D Expenditure, $Million, 2018-2020
Figure 6: Oxford Nanopore Technologies plc: SWOT Analysis
Figure 126: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 127: Pacific Biosciences of California, Inc.: Overall Financials, 2018-2020
Figure 128: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2018-2020
Figure 129: Pacific Biosciences of California, Inc.: Revenue (by Region), 2018-2020
Figure 130: Pacific Biosciences of California, Inc.: R&D Expenditure, 2018-2020
Figure 131: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 132: PerkinElmer, Inc.: Overall Financials, 2018-2020
Figure 133: PerkinElmer, Inc.: SWOT Analysis
Figure 134: QIAGEN: Portfolio
Figure 135: QIAGEN: Overall Financials, 2018-2020
Figure 136: QIAGEN: Revenue (by Segment), 2018-2020
Figure 137: QIAGEN: Revenue (by Region), 2018-2020
Figure 138: QIAGEN: R&D Expenditure, 2018-2020
Figure 139: QIAGEN: SWOT Analysis
Figure 140: Quantapore, Inc.: Product Portfolio
Figure 141: Quantapore, Inc.: SWOT Analysis
Figure 142: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 143: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 144: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018-2020
Figure 145: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 146: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 147: Thermo Fisher Scientific Inc.: SWOT Analysis
Market Report Coverage
Long-Read Sequencing Market |
|||
Base Year |
2020 |
Market Size in 2020 |
$504.7 Million |
Forecast Period |
2021-2030 |
Value Projection and Estimation by 2030 |
$3,305.5 Million |
CAGR During Forecast Period |
21.15% |
Number of Tables |
09 |
Number of Pages |
195 |
Number of Figures |
147 |
Market Segmentation |
• Products (Systems, Kits and Assays, Software) and Services • Technology (Single-Molecule Real-Time (SMRT) Sequencing, Nanopore Sequencing, Synthetic Long-Read Sequencing, and Others) • Application (Oncology, Infectious Diseases, Rare Diseases, Genetic Disorders, Metabolic Disorders, and Translational Research) • End User (Academic and Research Institutions, Pharma and Biotech Companies, Clinical Laboratories, Hospitals and Clinics, and Other End Users) |
||
Regional Segmentation |
• North America: U.S., Canada • Europe: Germany, France, Italy, U.K., Spain, Netherland, Russia and Rest-of-the-Europe • Asia-Pacific: Japan, China, India, Australia, South Korea, Singapore, and Rest-of-APAC • Latin America: Brazil, Mexico, Rest-of-Latin America |
||
Growth Drivers |
• Decreasing Cost of Sequencing • Global Increase in Cancer Prevalence • Increasing Number of Population Genomics Initiatives |
||
Market Challenges |
• Lack of High Complexity Genomic Testing Centers in High Potential Markets • Challenges Pertaining to Genomic Data Centers • Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities |
||
Market Opportunities |
• Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations • Novel Diagnostic Applications |
||
Key Companies Profiled |
Agilent Technologies, Inc., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bionano Genomics, Inc., Circulomics Inc, F. Hoffmann-La Roche Ltd, Illumina, Inc., Longas Technologies Pty Ltd, Novogene Co., Ltd., Oxford Nanopore Technologies plc, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN, Quantapore, Inc., Thermo Fisher Scientific Inc. |
Key Questions Answered in this Report:
• How is long-read sequencing revolutionizing the field of next generation sequencing?
• What are the major market drivers, challenges, and opportunities in the global long-read sequencing market?
• What are the underlying structures resulting in the emerging trends within the global long-read sequencing market?
• How is the COVID-19 pandemic impacting the global long-read sequencing market landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to long-read sequencing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region for the development of long-read sequencing?
• How is each segment of the market expected to grow during the forecast period 2021-2030, and what is the anticipated revenue to be generated by each segment? Following are the segments:
• Products (systems, kits, and assays, software) and services
• Technology (single-molecule real-time (SRMT) sequencing, nanopore sequencing, synthetic long-read sequencing, and others)
• Application (oncology, infectious diseases, rare diseases, genetic disorders, metabolic disorders, and translational research)
• End user (academic and research institutions, pharma and biotech companies, clinical laboratories, hospitals and clinics, and other end users)
• Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global long-read sequencing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced in the global long-read sequencing market?
Report Summary
Long-read sequencing is overcoming early limitations in throughput and accuracy. The sequencing methods are broadening their application domains in genomics and data analysis. Dedicated analysis tools that consider the characteristics of long-read data sequencing are required, while the fast pace of development of such tools can be overwhelming. Long-read sequencing, or third-generation sequencing, offers several advantages over short-read sequencing. However, short-read sequencers such as Illumina’s NovaSeq, HiSeq, NextSeq, and MiSeq instruments, BGI’s MGISEQ and BGISEQ models, or Thermo Fisher’s Ion Torrent sequencers produce reads of up to 600 bases for long-read sequencing technologies routinely generate reads over 10 kb. Long-read sequencing analysis is a process that helps researchers and clinicians to analyze and interpret data generated by modern genomics technologies, such as NGS and PCR. As sequencing technologies are producing millions of high-quality reads per run, the adoption of robust long-read sequencing solutions has increased significantly over the past few years.
Our healthcare experts have found long-read sequencing to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 21.15% over the forecast period of 2021-2030.
Figure: Global Long-Read Sequencing Market Snapshot
Source: BIS Research Analysis
Factors fueling the growth of the market include a decrease in the cost of sequencing, a global increase in cancer prevalence, and an increase in the number of population genomics initiatives. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth. The lack of high complexity genomic testing centers in high potential markets, challenges pertaining to genomic data storage, and scarcity of knowledge dissemination pertaining to advanced diagnostic capabilities are the major challenges for the growth of the market. Further, some of the opportunities, such as massive scope for adoption of genomic data analysis software in emerging nations, provide growth to the market.
Within the research report, the market has been segmented on the basis of products and services, technology, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the cases of cancer and genetic disorders on the global level has created a buzz among companies to invest in the advanced technologies of next-generation sequencing.
Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Global Long-Read Sequencing Market
Focus on Products and Services, Technology, Application, End User, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2030
Frequently Asked Questions
The long-read sequencing market is expected to grow at a CAGR of 21.15% during the forecast period from 2021-2030.
Some of the opportunities that have the potential to open the unexplored areas, including massive scope for adoption of genomic data analysis software in emerging nations and novel diagnostic applications.
Factors driving the growth market include decreasing cost of sequencing, global increase in cancer prevalence, and increasing number of population genomics initiatives.
Areas of applications where long-read sequencing can be used include oncology, infectious diseases, rare diseases, genetic disorders, metabolic disorders, and translational research.
Some of the players operating in the market include Agilent Technologies, Inc., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bionano Genomics, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Longas Technologies Pty Ltd, Novogene Co., Ltd., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN N.V., Quantapore, Inc., and Thermo Fisher Scientific Inc.